Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review

Pancreatic adenocarcinoma has a  5-year overall survival rate of 9 %, with an outlook of becoming the second leading cause of cancer mortality in the USA by 2030. Familial pancreatic cancer and genetic predisposition syndromes have attracted more interest in the perspective of targeted therapy. Vari...

Full description

Bibliographic Details
Main Authors: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, A. A. Izmailov, I. A. Menshikova, N. I. Sultanbaeva, E. V. Popova, L. A. Khammatova
Format: Article
Language:English
Published: Bashkir State Medical University 2022-06-01
Series:Креативная хирургия и онкология
Subjects:
Online Access:https://www.surgonco.ru/jour/article/view/674